CAR-macrophage: A new immunotherapy candidate against solid tumors

Biomedicine & Pharmacotherapy

Xuewen Tan¹  Zhiying Yu²  Wei Wei³  Yilong Fang⁴  Yizhao Chen⁴  Wenming Hong⁴  Haifeng Jiang⁴  Dafei Han⁴  Jiajie Tu⁴  Zhen Xu⁴ 

[1] Shenzhen Second People's Hospital, Shenzhen, China;Department of Gynecology, The First Affiliated Hospital of Shenzhen University, Health Science Center;Department of Neurosurgery, The First Affiliated Hospital of Anhui Medical University, China;Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-Inflammatory and Immune Medicine, Hefei, China;

关键词: CAR-M;    Phagocytosis;    Solid tumor;    CAR-T;    CAR-NK;    Immunotherapy;   

DOI  :  

来源: DOAJ

【 摘 要 】

Chimeric antigen receptor (CAR)-T cell therapy has been shown to be an effective treatment for hematological tumors, but the treatment of solid tumors still lacks effectiveness. In the tumor microenvironment, macrophages are the innate immune cells with the highest infiltration rate. Tumor-associated macrophages (TAMs) stimulate angiogenesis, increase tumor invasion, and mediate immunosuppression. Because macrophages can infiltrate solid tumor tissue and interact with almost all cellular components in the tumor microenvironment (including tumor cells, immune cells such as T-cells, NK cells, DCs, and other resident non-immune cells), researchers are trying to use macrophages modified with CAR (CAR-M) against solid tumors. This review describes recent reports of CAR-M-based tumor treatments and summarizes their shortcomings and future applications.

【 授权许可】

Unknown